Backs Q2 revenue view $270M-$280M, consensus $283.97M . Raises Q2 adjusted EBITDA view to $25M-$31M from $22M-$30M. The company said, “On May 12th, 2025, it was announced that the United States would temporarily lower tariff rates on imports from China from 145% to 30% for 90 days. As a result of this announcement, the Company has updated its previously issued second quarter and full year 2025 outlook. The table below contains the previous and updated guidance.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMCL:
- Omnicell announces new products for perioperative and clinic settings
- Omnicell opens new Innovation Lab in Austin, Texas
- Omnicell upgraded to Overweight from Equal Weight at Wells Fargo
- Positive Outlook for Omnicell: Strong Demand and Market Stability Drive Buy Rating
- Omnicell price target lowered to $53 from $64 at Craig-Hallum